DSG2 and systemic sclerosis: These observations are supported by the clinical manifestation linked to DSG2 ‘loss of function’ in microvascular endothelial cells identified in patients with systemic sclerosis [13, 43] and of microvascular density being associated with MM progression [30, 31].